natgillin/translations-raw huggingface dataset:
No dose adjustment is necessary for efavirenz.
Nije potrebno prilagođavati dozu ni jednog lijeka.
No dose adjustment is necessary for efavirenz.
Nije potrebno prilagođivati dozu ni jednog lijeka.
No dose adjustment is necessary for efavirenz.
prilagođavati dozu efavirenza.
No dose adjustment is necessary for either medicinal product.
Nije potrebno prilagođavati dozu
No dose adjustment is necessary for either medicinal product.
Nije potrebno prilagođavati dozu ni jednog lijeka.
No dose adjustment is necessary for either medicinal product.
Nije potrebno prilagođavati dozu niti jednog od navedenih lijekova.
No dose adjustment is necessary for either medicinal product.
Nije potrebno prilagođivati dozu ni jednog lijeka.
No dose adjustment is necessary for either medicinal product.
Nije potrebno prilagođivati dozu niti jednog lijeka.
No dose adjustment is necessary for either medicinal product.
Zbog ograničenosti dostupnih
No dose adjustment is necessary for elderly patients; however the clinical experience in elderly patients is limited.
Dozu nije potrebno prilagoĎavati kod starijih bolesnika; meĎutim klinička iskustva sa starijim bolesnicima su ograničena.
No dose adjustment is necessary for older people (see section 5.1 and 5.2).
Nije potrebna prilagodba doze u starijih osoba (vidjeti dio 5.1 i 5.2).
No dose adjustment is necessary for paracetamol when administered with Exviera + ombitasvir/paritaprevir/rito navir.
prilagođavati dozu za ciklobenzaprin; primijeniti veću dozu ako
No dose adjustment is necessary for patients with hepatic impairment (see section 5.2).
U bolesnika s oštećenjem funkcije jetre nije potrebna prilagodba doze (vidjeti dio 5.2).
No dose adjustment is necessary for patients with hepatic impairment (see section 5.2).
U bolesnika s oštećenjem jetre nije potrebna prilagodba doze (vidjeti dio 5.2).
No dose adjustment is necessary for patients with hepatic impairment.
U bolesnika s oštećenjem funkcije jetre nije potrebna prilagodba doze.
No dose adjustment is necessary for patients with impaired hepatic function.
Za bolesnike s oštećenom funkcijom bubrega nije potrebno prilagođavanje doze.
No dose adjustment is necessary for patients with impaired hepatic function.
Za bolesnike s oštećenom funkcijom jetre nije potrebno prilagođavanje doze.
No dose adjustment is necessary for patients with impaired renal function.
Za bolesnike s oštećenom funkcijom bubrega nije potrebno prilagođavanje doze.
No dose adjustment is necessary for patients with mild and moderate hepatic impairment based on a study conducted in Child-Pugh grade B subjects.
Na temelju ispitivanja provedenog kod ispitanika s Child-Pugh stadijem B, u bolesnika s blagim i umjerenim oštećenjem funkcije jetre nije potrebna prilagodba doze.
No dose adjustment is necessary for patients with mild and moderate renal impairment (eGFR 60 to 89 and 30 to 59 ml/min/1.73m2, respectively) (see sections 4.4, 4.8, 5.1, 5.2).
Nije potrebno prilagođavati dozu u bolesnika s blagim i umjerenim oštećenjem bubrežne funkcije (procijenjena brzina glomerularne filtracije [eGFR] od 60-89 odnosno 30-59 ml/min/1,73 m2) (vidjeti dijelove 4.4, 4.8, 5.1 i 5.2).
No dose adjustment is necessary for patients with mild hepatic impairment.
U bolesnika s blagim oštećenjem funkcije jetre nije potrebno prilagođavati dozu.
No dose adjustment is necessary for patients with mild or moderate renal impairment where serum creatinine is equal or below 200 µmol/l (2.3 mg/dl) or where creatinine clearance (measured or estimated) is equal or greater than 30 ml/min.
Nije potrebna prilagodba doze u bolesnika s blagim ili umjerenim oštećenjem funkcije bubrega u kojih je kreatinin u serumu jednak ili manji od 200 µmol/l (2,3 mg/dl) ili u kojih je klirens kreatinina (mjeren ili procijenjen) jednak ili veći od 30 ml/min.
No dose adjustment is necessary for patients with mild, moderate or severe hepatic impairment (Child- Pugh Class A, B or C, respectively).
Nije potrebna prilagodba doze u bolesnika s blagim, umjerenim ili teškim oštećenjem funkcije jetre (Child-Pugh stadij A, B, odnosno C).
No dose adjustment is necessary for patients with renal impairment (see section 5.2).
Nije potrebna prilagodba doze za bolesnike s oštećenjem funkcije bubrega (vidjeti dio 5.2).
No dose adjustment is necessary for patients with renal impairment or for patients with end stage renal disease undergoing haemodialysis (see section 5.2).
Nije potrebno prilagođavati dozu u bolesnika s blagim oštećenjem funkcije bubrega ili u terminalnoj fazi bolesti bubrega koji su na hemodijalizi (vidjeti dio 5.2).
No dose adjustment is necessary for patients with renal insufficiency.
Nije potrebno prilagođavati dozu u bolesnika sa zatajivanjem bubrega.
No dose adjustment is necessary for the elderly based on age alone (see section 5.2).
U starijih osoba nije potrebno prilagođavati dozu samo na temelju dobi (vidjeti dio 5.2).
No dose adjustment is necessary for the older people.
Nije potrebna prilagodba doze za starije ljude.
No dose adjustment is necessary for the older people.
Nije potrebna prilagodba doze za starije osobe.
No dose adjustment is necessary for the paediatric population.
Nije potrebno prilagođavati dozu pedijatrijskoj populaciji.
No dose adjustment is necessary for the paediatric population.
Nije potrebno prilagođavati dozu u pedijatrijskoj populaciji.
No dose adjustment is necessary for these sub- populations.
Nije potrebno prilagođavati dozu u tim potpopulacijama.
No dose adjustment is necessary for zolpidem.
dozu za zolpidem.
No dose adjustment is necessary in elderly patients ( ≥ 65 years of age), see section 5.1. There is limited experience with BLINCYTO in patients ≥ 75 years of age.
Nije potrebna prilagodba doze u starijih bolesnika (u dobi od ≥ 65 godina), vidjeti dio 5.1. Iskustvo s primjenom lijeka BLINCYTO u osoba u dobi od ≥ 75 godina je ograničeno.
No dose adjustment is necessary in elderly patients or in those with impaired renal or liver function.
Za starije bolesnike i one s oštećenom funkcijom jetre ili bubrega nije potrebna prilagodba doze.
No dose adjustment is necessary in elderly patients.
Nije potrebna prilagodba doze u starijih bolesnika.
No dose adjustment is necessary in elderly patients.
U bolesnika starije dobi nije potrebno prilagođavanje doze.
No dose adjustment is necessary in elderly patients.
U starijih bolesnica prilagodba doze nije potebna.
No dose adjustment is necessary in mildly and moderately renally impaired patients (CLCR
Kod bolesnika s blagim do umjerenim oštećenjem bubrega ne treba prilagođavati dozu (CLCR
No dose adjustment is necessary in mildly and moderately renally impaired patients (CLCR
Kod bolesnika s blagim do umjerenim oštećenjem bubrega ne treba prilagođavati dozu (CLCR >
No dose adjustment is necessary in patients 65 years and older (see section 5.2).
Nije potrebno prilagođavati dozu u bolesnika u dobi od 65 i više godina (vidjeti dio 5.2).
No dose adjustment is necessary in patients with hepatic impairment (see section 5.2).
Nije potrebna prilagodba doze u bolesnika s oštećenjem jetre (vidjeti dio 5.2).
No dose adjustment is necessary in patients with hepatic impairment (see section 5.2).
U bolesnika s oštećenjem funkcije jetre nije potrebna prilagodba doze (vidjeti dio 5.2).
No dose adjustment is necessary in patients with hepatic impairment.
Nije potrebno prilagođavanje doze u bolesnika s oštećenjem jetre.
No dose adjustment is necessary in patients with impaired renal function (creatinine clearance
Nije potrebna prilagodba doze u bolesnika s oštećenom funkcijom bubrega (klirens kreatinina
No dose adjustment is necessary in patients with impaired renal function (creatinine clearance >4 ml/min) (see section 5.2).
Nije potrebna prilagodba doze u bolesnika s oštećenom funkcijom bubrega (klirens kreatinina > 4 ml/min) (vidjeti dio 5.2).
No dose adjustment is necessary in patients with impaired renal function.
Nije potrebna prilagodba doze u bolesnika s oš teć enom funkcijom bubrega.
No dose adjustment is necessary in patients with mild hepatic impairment (Child-Pugh Class A).
Nije potrebno prilagođavanje doze u bolesnika s blagim oštećenjem funkcije jetre (stupanj A prema Child- Pughovoj klasifikaciji).
No dose adjustment is necessary in patients with mild hepatic impairment.
Nije potrebno prilagođavati dozu u bolesnika s blagim oštećenjem jetre.
No dose adjustment is necessary in patients with mild or moderate hepatic impairment (Child-Pugh classes A and B) (see section 5.2).
Nije potrebna prilagodba doze u bolesnika s blagim ili umjerenim oštećenjem funkcije jetre (Child- Pugh stadij A ili B) (vidjeti dio 5.2).
No dose adjustment is necessary in patients with mild or moderate hepatic impairment (Child-Pugh Classes A and B) (see sections 4.4 and 5.2).
Dozu nije potrebno prilagoĎavati kod bolesnika s blagim ili umjerenim oštećenjem funkcije jetre (Child-Pugh stadiji A i B) (vidjeti dio 4.4. i 5.2).
No dose adjustment is necessary in patients with mild or moderate hepatic impairment.
U bolesnica s blagim do umjerenim oštećenjem jetre prilagodba doze nije potrebna.
No dose adjustment is necessary in patients with mild or moderate renal impairment (see section 5.2).
U bolesnika s blagim ili umjerenim oštećenjem bubrežne funkcije nije potrebno prilagođavati dozu (vidjeti dio 5.2).
No dose adjustment is necessary in patients with mild or moderate renal impairment.
Kod bolesnika s blagim ili umjerenim oštećenjem funkcije bubrega nije potrebno prilagođavanje doze.
No dose adjustment is necessary in patients with mild renal impairment (CrCL 50- ≤ 80 mL/min).
Nije potrebno prilagođavanje doze u bolesnika s blagim oštećenjem bubrega (CrCL 50- ≤ 80 mL/min).
No dose adjustment is necessary in patients with mild renal impairment (creatinine clearance 50 - 80 ml/min) (see section 5.2).
U bolesnika s blago oštećenom funkcijom bubrega (klirens kreatinina 50 – 80 ml/min) dozu ne treba prilagođavati (vidjeti dio 5.2).
No dose adjustment is necessary in patients with mild renal impairment (creatinine clearance 50 - 80 ml/min) (see section 5.2).
U bolesnika s blago oštećenom funkcijom bubrega (klirens kreatinina 50 – 80 ml/min) dozu ne treba prilagođavati (vidjeti dio 5.2.).
No dose adjustment is necessary in patients with mild renal impairment (creatinine clearance 50 - 80 ml/min) or moderate renal impairment (creatinine clearance 30 - 49 ml/min) (see section 5.2).
U bolesnika s blago (klirens kreatinina od 50 do 80 ml/min) ili umjereno (klirens kreatinina od 30 do 49 ml/min) oštećenom funkcijom bubrega nije potrebna prilagodba doze (vidjeti dio 5.2).
No dose adjustment is necessary in patients with mild to moderate hepatic impairment (see section 5.2).
Nije potrebna prilagodba doze kod bolesnika s blagim do umjerenim oštećenjem jetre (vidjeti dio 5.2).
No dose adjustment is necessary in patients with mild to moderate renal impairment (GFR
Nije potrebna prilagodba doze u bolesnika s blagim do umjerenim oštećenjem bubrežne funkcije (GFR
No dose adjustment is necessary in patients with mild to moderate renal impairment.
Nije potrebno prilagođavati dozu kod bolesnika s blagim do umjerenim oštećenjem funkcije bubrega.
No dose adjustment is necessary in patients with mild to moderate renal impairment.
Nije potrebno prilagođavati dozu u bolesnika s blagim do umjerenim oštećenjem bubrega.
No dose adjustment is necessary in patients with renal impairment (see section 5.2).
Nije potrebna prilagodba doze u bolesnika s oštećenjem funkcije bubrega (vidjeti dio 5.2).
No dose adjustment is necessary in patients with renal impairment, including patients with end-stage renal disease (see section 5.2).
Dozu nije potrebno prilagoĎavati kod bolesnika s oštećenjem funkcije bubrega; uključujući i bolesnike s bolesti bubrega u terminalnoj fazi (vidjeti dio 5.2).
No dose adjustment is necessary in patients with renal impairment.
Nije potrebna prilagodba doze kod bolesnika koji imaju oštećenje funkcije bubrega.
No dose adjustment is necessary in patients with renal impairment.
Prilagodba doze nije potrebna u bolesnika s oštećenjem funkcije bubrega.
No dose adjustment is necessary in patients with renal insufficiency.
Prilagođavanje doze za bolesnike s bubrežnom insuficijencijom nije potrebno.
No dose adjustment is necessary in the absence of integrase class resistance.
Ako ne postoji rezistencija na skupinu inhibitora integraze, nije potrebno prilagođavati dozu.
No dose adjustment is necessary in the elderly (see sections 4.4 and 5.2).
Nije potrebno prilagođavati dozu u starijih osoba (vidjeti dijelove 4.4 i 5.2).
No dose adjustment is necessary in this population.
Nije potrebno prilagođavati dozu u toj populaciji.
No dose adjustment is necessary in TIH patients with serum creatinine < 400 µmol/l or < 4.5 mg/dl (see section 4.4).
Nije potrebna prilagodba doze u bolesnika s hiperkalcemijom izazvanom tumorom i vrijednostima kreatinina u serumu < 400 μmol/l ili 4,5 mg/dl (vidjeti dio 4.4).
No dose adjustment is necessary when CYP3A inhibitors are initiated in patients currently taking Orkambi.
Kada se započinje liječenje inhibitorima CYP3A, u bolesnika koji već uzimaju Orkambi nije potrebna prilagodba doze.
No dose adjustment is necessary when Triumeq is combined with nucleoside reverse transcript inhibitors.
Nije potrebno prilagođavati dozu kada se Triumeq primjenjuje u kombinaciji s nukleozidnim inhibitorima reverzne transkriptaze.
No dose adjustment is necessary when Xtandi is co-administered with inducers of CYP2C8 or CYP3A4.
Nije potrebna prilagodba doze kad se Xtandi primjenjuje istovremeno s induktorima CYP2C8 ili CYP3A4.
No dose adjustment is needed (see section 5.2).
Nije potrebno prilagođavati dozu (vidjeti dio 5.2).
No dose adjustment is needed for elderly patients (see section 4.4).
Za starije bolesnike nije potrebna prilagodba doze (vidjeti dio 4.4).
No dose adjustment is needed for elderly patients (see section 4.4).
Za starije bolesnike prilagodba doze nije potrebna (vidjeti dio 4.4).
No dose adjustment is needed for elderly patients.
Nije potrebno prilagođavati dozu u starijih bolesnika.
No dose adjustment is needed for mirabegron when administered with CYP2D6 inhibitors or in patients who are CYP2D6 poor metabolisers.
Nema potrebe prilagoĎavanja doze mirabegrona kada se primjenjuje s inhibitorima CYP2D6 ili kod bolesnika koji slabo metaboliziraju supstrat CYP2D6.
No dose adjustment is needed for mirabegron when administered with CYP2D6 inhibitors or in patients who are CYP2D6 poor metabolisers.
Nema potrebe prilagoĎavati dozu mirabegrona kada se primjenjuje s inhibitorima CYP2D6 ili kod bolesnika koji slabo metaboliziraju supstrat CYP2D6.
No dose adjustment is needed for mirabegron when administered with therapeutic doses of rifampicin or other CYP3A or P-gp inducers.
Nije potrebno prilagoĎavati dozu mirabegrona kada se primjenjuje s terapijskim dozama rifampicina ili drugih induktora CYP3A ili P-gp.
No dose adjustment is needed for patients 65 years of age and older (see section 5.2).
Prilagodba doze nije potrebna za bolesnike u dobi od 65 godina i starije (vidjeti dio 5.2).
No dose adjustment is needed for patients with mild or moderate renal impairment.
Nije potrebno prilagođavati dozu u bolesnika s blagim ili umjerenim oštećenjem bubrežne funkcije.
No dose adjustment is needed for patients with mild to moderate hepatic impairment.
Kod bolesnika s blagim do umjerenim oštećenjem jetre ne treba prilagođavati dozu.
No dose adjustment is needed in elderly patients (see section 5.2).
Nije potrebno prilagođavati dozu u starijih bolesnika (vidjeti dio 5.2).
No dose adjustment is needed in elderly patients.
Kod starijih bolesnika nije potrebno prilagođavati dozu.
No dose adjustment is needed in elderly patients.
Prilagodba doze nije potrebna u starijih bolesnika.
No dose adjustment is needed in patients based on weight.
Nije potrebno prilagođavati dozu na temelju tjelesne težine bolesnika.
No dose adjustment is needed in patients with hepatic impairment (see section 5.2)
Nije potrebna prilagodba doze u bolesnika s oštećenjem funkcije jetre (vidjeti dio 5.2).
No dose adjustment is needed in patients with hepatic impairment (see section 5.2).
Nije potrebna prilagodba doze u bolesnika s oštećenjem funkcije jetre (vidjeti dio 5.2).
No dose adjustment is needed in patients with hepatic impairment.
Kod bolesnika s oštećenjem funkcije jetre nije potrebno prilagođavati dozu lijeka.
No dose adjustment is needed in patients with mild, moderate or severe renal insufficiency (see section 4.4 and section 5.2).
U bolesnika s blagim, umjerenim ili teškim oštećenjem bubrežne funkcije nije potrebno prilagođavati dozu (vidjeti dio 4.4 i dio 5.2).
No dose adjustment is needed in patients with renal impairment.
Kod bolesnika s oštećenom funkcijom bubrega nije potrebno prilagođavati dozu lijeka.
No dose adjustment is needed in patients with renal insufficiency.
Prilagodba doze nije potrebna kod bolesnika s bubrežnom insuficijencijom.
No dose adjustment is needed.
Nije potrebno prilagođavati dozu.
No dose adjustment is normally required for elderly patients.
Prilagođavanje doze obično nije potrebno kod starijih bolesnika.
No dose adjustment is recommended (see section 4.2).
Nije potrebna prilagodba doze (vidjeti dio 4.2).
No dose adjustment is recommended based on age (see section 5.2).
Ne preporučuje se prilagodba doze u skladu s dobi (vidjeti dio 5.2).
No dose adjustment is recommended based on age alone.
Nije potrebna prilagodba doze samo na temelju dobi.
No dose adjustment is recommended based on age.
Ne preporučuje se prilagođavati dozu s obzirom na dob.
No dose adjustment is recommended for individuals older than 65 years of age (see section 5.2).
Ne preporuča se prilagodba doze u osoba starijih od 65 godina (vidjeti dio 5.2.).
No dose adjustment is recommended for mild to moderate renal impairment (creatinine clearance >30 ml/min).
Ne preporučuje se prilagođavanje doze kod bolesnika s blagim do umjerenim oštećenjem bubrega (klirens kreatinina > 30 ml/min).
No dose adjustment is recommended for patients with mild hepatic impairment.
Nije potrebna prilagodba doze u bolesnica s blagim oštećenjem jetrene funkcije.
No dose adjustment is recommended for patients with mild renal impairment.
Ne preporučuje se prilagodba doze u bolesnika s blagim oštećenjem bubrežne funkcije.
No dose adjustment is recommended for patients with mild renal impairment.
Ne preporučuje se prilagođavati dozu u bolesnika s blagim oštećenjem funkcije bubrega.
No dose adjustment is recommended for patients with renal impairment (see section 5.2).
Ne preporuča se prilagodba doze u bolesnika s oštećenjem funkcije bubrega (vidjeti dio 5.2.).
No dose adjustment is recommended for this patient population (see sections 4.4 and 5.2).
Nije preporučena prilagodba doze u ovoj populaciji bolesnika (vidjeti dijelove 4.4 i 5.2).
No dose adjustment is recommended in patients with mild and moderate renal impairment.
Ne preporučuje se prilagodba doze u bolesnika s blagim i umjerenim oštećenjem funkcije bubrega.
No dose adjustment is recommended in patients with mild to moderate renal impairment (see sections 4.4 and 5.2).
Prilagodba doze ne preporučuje u bolesnika s blagim do umjerenim oštećenjem bubrega (vidjeti dijelove 4.4 i 5.2).
No dose adjustment is recommended.
Ne preporučuje se prilagođavanje doze.
No dose adjustment is recommended.
Ne preporučuje se prilagođivati dozu.
No dose adjustment is recommended.
Nije nužna prilagodba doziranja.
No dose adjustment is required
Prilagodba doze nije potrebna kada
No dose adjustment is required (see section 4.2).
Nije potrebno prilagodba doze (vidjeti dio 4.2).
No dose adjustment is required (see section 5.1).
Nije potrebno prilagođavati dozu (vidjeti dio 5.1).
No dose adjustment is required (see section 5.2 ).
Nije potrebna prilagodba doze (vidjeti dio 5.2).
No dose adjustment is required (see section 5.2).
Nije potrebno prilagođavanje doze (vidjeti dio 5.2).
No dose adjustment is required (see sections 5.1 and 5.2).
Nije potrebno prilagođivati dozu (vidjeti dijelove 5.1 i 5.2).
No dose adjustment is required based on age (see section 5.2).
Nije potrebno prilagođavati dozu s obzirom na dob (vidjeti dio 5.2).
No dose adjustment is required based on gender.
Nije potrebno prilagođavati dozu s obzirom na spol.
No dose adjustment is required following the switch from an efavirenz-containing regimen.
Nije potrebna prilagodba doze nakon prebacivanja sa režima koji je sadržavao efavirenz.
No dose adjustment is required for darunavir/ritonavir in patients with renal impairment (see sections
U bolesnika s oštećenjem bubrega nije potrebna prilagodba doze darunavira/ritonavira (vidjeti dijelove
No dose adjustment is required for elderly patients (≥ 65 years) (see sections 5.1 and 5.2).
Nije potrebno prilagođavati dozu u starijih bolesnika (≥ 65 godina) (vidjeti dijelove 5.1 i 5.2).
No dose adjustment is required for elotuzumab in patients over 65 years of age (see section 5.2).
Nije potrebno prilagođavati dozu elotuzumaba u bolesnika starijih od 65 godina (vidjeti dio 5.2).
No dose adjustment is required for lopinavir/ritonavir during pregnancy and postpartum.
Nije potrebna prilagodba doze lopinavira/ritonavira tijekom trudnoće i poslijeporođajnog razdoblja.
No dose adjustment is required for patients with cancer-related pain (see sections 4.3 and 4.4).
Nije potrebna prilagodba doze u bolesnika s boli uzrokovanom rakom (vidjeti dijelove 4.3 i 4.4).
No dose adjustment is required for patients with hepatic impairment (see section 5.2).
Nije potrebno prilagođavati dozu u bolesnika s oštećenjem funkcije jetre(vidjeti dio 5.2).
No dose adjustment is required for patients with hepatic impairment.
Za bolesnike s oštećenjem jetre nije potrebno podešavati dozu.
No dose adjustment is required for patients with mild or moderate renal impairment (creatinine clearance 60–90 ml/min and 30–59 ml/min, respectively).
Nije potrebno prilagođavanje doze u bolesnika s blažim ili umjerenim oštećenjem bubrega (klirens kreatinina 60-90 ml/min odnosno 30-59 ml/min).
No dose adjustment is required for patients with mild to moderate hepatic impairment.
Nije potrebna prilagodba doze u bolesnika s blagim do umjerenim oštećenjem funkcije jetre.
No dose adjustment is required for patients with mild to moderate renal impairment.
Nije potrebna prilagodba doze u bolesnika s blagim do umjerenim oštećenjem funkcije bubrega.
No dose adjustment is required for patients with mild, moderate, or severe renal impairment (see section 5.2).
Nije potrebna prilagodba doze za pacijente s blagim, umjerenim ili teškim oštećenjem funkcije bubrega (vidjeti dio 5.2).
No dose adjustment is required for patients with renal impairment (see section 5.1).
Nije potrebno prilagođivati dozu u bolesnika s oštećenjem funkcije bubrega (vidjeti dio 5.1).
No dose adjustment is required for patients with renal impairment.
Nije potrebno prilagođavanje doze u bolesnika s oštećenjem bubrega.
No dose adjustment is required for pomalidomide.
Nije potrebna prilagodba doze pomalidomida.
No dose adjustment is required for rilpivirine hydrochloride in patients with mild or moderate hepatic impairment (CPT Score A or B).
Nije potrebna prilagodba doze rilpivirinklorida u pacijenata s blagim ili umjerenim oštećenjem jetre (CPT stadij A ili B).
No dose adjustment is required for this patient population (see sections 4.8 and 5.2).
U ovoj populaciji bolesnika nije potrebna prilagodba doze (vidjeti dijelove 4.8 i 5.2).
No dose adjustment is required for thrombocytopenic patients with chronic HCV and mild hepatic impairment (Child-Pugh score ≤ 6).
Nije potrebna prilagodba doze u bolesnika s trombocitopenijom i kroničnim HCV-om i blagim oštećenjem jetre (≤ 6 bodova po Child-Pugh ljestvici).
No dose adjustment is required in elderly patients (see section 5.2).
Nije potrebno prilagođavati dozu u starijih bolesnika (vidjeti dio 5.2).
No dose adjustment is required in elderly patients (see section 5.2).
Prilagodba doze nije potrebna kod starijih bolesnika (vidjeti dio 5.2).
No dose adjustment is required in hepatically impaired patients (see section 5.2).
Nije potrebna prilagodba doze u bolesnika s oštećenjem jetre (vidjeti dio 5.2).
No dose adjustment is required in older people ≥ 65 years of age.
Nije potrebna prilagodba doze u starije populacije u dobi od 65 ili više godina.